| abstract |
This invention relates to novel guanamine cycloalkyl compounds, and in particular to compounds of formula I as described herein, and salts and N-oxides thereof. Such compounds have valuable therapeutic properties and are particularly useful in the treatment of diseases responsive to dopamine D3 receptor modulation. □ In formula I, the variable has the following meaning: m is 1 or 2, n is 1 or 2, and A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is hydrogen or C1-C3-alkyl, R2 It is selected from the group consisting of hydrogen and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, and R4 is branched C4-C6 alkyl or branched. C4-C6 alkyl, and R5 is an oxygen-containing group, such as C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1 -C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolane, fluorinated oxolyl, C3-C5 naphthenic A fluorinated C3-C5 cycloalkyl group, a C3-C5 cycloalkoxy-C1-C4-alkyl group, and a fluorinated C3-C5 cycloalkoxy-C1-C4-alkyl group. |